BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 08/12/2022

FDA Clears NORFLEX (Orphenadrine Citrate) for Continued Sale

The US Food and Drug Administration (FDA) has determined that NORFLEX (Orphenadrine Citrate) Injection and Extended-Release Tablet were not withdrawn from sale due to safety or effectiveness concerns, allowing the agency to continue approving abbreviated new drug applications (ANDAs) for the product.

Source: Federal Register — Food and Drug AdministrationOpen original release →